Biomarin Pharmaceutical Inc
NASDAQ:BMRN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
61.93
99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Biomarin Pharmaceutical Inc
Biomarin Pharmaceutical Inc
Total Current Assets
Biomarin Pharmaceutical Inc
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
Total Current Assets
$3.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Assets
$27.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Assets
$13.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Assets
$26.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Assets
$9.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
15%
|
CAGR 10-Years
20%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Assets
$19.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
22%
|
CAGR 10-Years
24%
|
|
Biomarin Pharmaceutical Inc
Glance View
In the bustling hub of biotechnology innovation, BioMarin Pharmaceutical Inc. stands as a notable entity, driven by its mission to transform medical research into meaningful treatments for patients worldwide. Founded in 1997 and headquartered in San Rafael, California, BioMarin has carved a niche in the competitive landscape by specializing in therapies for rare genetic diseases. The company navigates the arduous and often uncertain path of drug development by targeting serious, and typically overlooked, medical conditions. BioMarin's expertise lies in leveraging cutting-edge genetic knowledge and technological advances to develop biopharmaceuticals that address unmet medical needs. This focus not only guides its scientific explorations but also informs its business strategy, where the development of drugs like Vimizim and Palynziq for conditions such as Morquio A syndrome and phenylketonuria, respectively, have made substantial impacts. BioMarin's revenue stream is predominantly fueled by these specialized therapies that cater to niche markets, with patients who often have limited treatment alternatives. Unlike traditional pharmaceuticals, BioMarin's portfolio is characterized by its strategic focus on orphan diseases, allowing it to capitalize on regulatory incentives designed to encourage the development of treatments for rare disorders. This approach provides market exclusivity and premium pricing potential, contributing to its financial robustness. Additionally, BioMarin's continuous investment in research and development ensures a dynamic pipeline aiming to introduce new innovations. This cycle of discovery and commercialization effectively sustains its growth trajectory, allowing BioMarin to not only thrive financially but also deliver on its commitment to improve patient lives with ultra-rare conditions.
See Also
What is Biomarin Pharmaceutical Inc's Total Current Assets?
Total Current Assets
3.1B
USD
Based on the financial report for Sep 30, 2024, Biomarin Pharmaceutical Inc's Total Current Assets amounts to 3.1B USD.
What is Biomarin Pharmaceutical Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
11%
Over the last year, the Total Current Assets growth was 3%. The average annual Total Current Assets growth rates for Biomarin Pharmaceutical Inc have been 10% over the past three years , 10% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
